Roeleveld Peter P, Zwijsen Eline G
1 Department of Pediatric Intensive Care, Leiden University Medical Center, Leiden, The Netherlands.
World J Pediatr Congenit Heart Surg. 2017 May;8(3):321-331. doi: 10.1177/2150135117690104.
Paradoxical hypertension after repair of coarctation of the aorta is a well-known phenomenon. The pathogenesis involves the activation of the sympathetic nervous system (first phase) and renin-angiotensin system (second phase). Only a limited number of different treatment strategies have been published in the literature, without any comparative studies.
Our aim was to describe the current international practice variation surrounding pharmacological treatment currently being employed to treat paradoxical hypertension following the repair of coarctation of the aorta in children. We performed an online survey among 197 members of the Pediatric Cardiac Intensive Care Society. We also conducted a systematic review of the literature regarding the treatment of paradoxical hypertension.
Eighty-eight people (45%), from 62 different centers, responded and answered the questions regarding blood pressure control. Nitroprusside is the first drug of choice for initial blood pressure control in 66% of respondents, esmolol in 11%, labetalol in 11%, and angiotensin-converting enzyme inhibitors (ACEIs) are used by 3% of respondents. For oral blood pressure control after discharge from the pediatric intensive care unit, 75% of respondents use ACEIs, 18% use labetalol, and 12% use other beta-blockers (propranolol, carvedilol, atenolol, metoprolol). The systematic review identified 14 articles reporting pharmacological treatment of direct postoperative hypertension following coarctation repair.
There is wide practice variability, due to the lack of sufficient compelling evidence. The majority (66%) of caregivers use nitroprusside to control blood pressure in the acute postoperative phase. The ACEIs are the drug of choice for chronic blood pressure control.
主动脉缩窄修复术后出现的矛盾性高血压是一种众所周知的现象。其发病机制涉及交感神经系统激活(第一阶段)和肾素 - 血管紧张素系统激活(第二阶段)。文献中仅发表了有限数量的不同治疗策略,且无任何比较研究。
我们的目的是描述目前国际上针对儿童主动脉缩窄修复术后矛盾性高血压所采用的药物治疗的实践差异。我们对儿科心脏重症监护学会的197名成员进行了在线调查。我们还对关于矛盾性高血压治疗的文献进行了系统综述。
来自62个不同中心的88人(45%)回复并回答了有关血压控制的问题。66%的受访者将硝普钠作为初始血压控制的首选药物,11%选择艾司洛尔,11%选择拉贝洛尔,3%的受访者使用血管紧张素转换酶抑制剂(ACEIs)。对于儿科重症监护病房出院后的口服血压控制,75%的受访者使用ACEIs,18%使用拉贝洛尔,12%使用其他β受体阻滞剂(普萘洛尔、卡维地洛、阿替洛尔、美托洛尔)。系统综述确定了14篇报道主动脉缩窄修复术后直接术后高血压药物治疗的文章。
由于缺乏充分有力的证据,实践差异很大。大多数(66%)护理人员在术后急性期使用硝普钠控制血压。ACEIs是慢性血压控制的首选药物。